Research programme: nuclear receptor-targeting therapeutics - Genfit

Drug Profile

Research programme: nuclear receptor-targeting therapeutics - Genfit

Alternative Names: AD Inov collaborative programme; G-15750; TGFTX1; TGFTX3

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genfit
  • Class Small molecules
  • Mechanism of Action Cytoplasmic and nuclear receptor modulators; Nuclear receptor subfamily 1 group F member 3 antagonists; Peroxisome proliferator-activated receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cardiovascular disorders; Hepatic fibrosis; Metabolic disorders; Psoriasis; Respiratory tract disorders
  • Research Autoimmune disorders

Most Recent Events

  • 13 Mar 2018 Preclinical development for Alzheimer's-disease, Cardiovascular-disorders, Metabolic-disorders and Hepatic fibrosis and early research for Autoimmune-disorders is ongoing in France
  • 13 Mar 2018 Preclinical trials in Psoriasis in France (Topical)
  • 13 Mar 2018 Preclinical trials in Respiratory tract disorders in France (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top